ING Groep NV Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

ING Groep NV purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,444 shares of the biopharmaceutical company’s stock, valued at approximately $972,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the period. Groupama Asset Managment boosted its holdings in shares of Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after acquiring an additional 151,480 shares during the period. Finally, Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $895,816,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 7,740 shares of company stock worth $2,420,214. 0.86% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $291.22 on Thursday. The company has a market capitalization of $38.88 billion, a P/E ratio of 79.57 and a beta of 0.29. The company has a 50-day simple moving average of $306.05 and a 200 day simple moving average of $345.14. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $283.10 and a fifty-two week high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the business earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.